CoChat
Sign Up
Cited by 223Schizophrenia research and treatmentCardiac Health and Mental HealthLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Open access
Daumit, Gail L., Goff, Donald C., Meyer, Jonathan M., Davis, Vicki G., Nasrallah, Henry A., McEvoy, Joseph P., Rosenheck, Robert, Davis, Sonia M., Hsiao, John K., Stroup, T. Scott, Lieberman, Jeffrey A.·2008·Schizophrenia Research
DOI 10.1016/j.schres.2008.07.006PMC PMC2614656
Open this paper in CoChat — free account

Abstract

Objective Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula.Method Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.Results The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments.Conclusions These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.schres.2008.07.006

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 44 references

Cited by

Sorted by citations

Items 101–200 of 223

Related

See all

Metadata

Authors
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., & Lieberman, J. A.
Affiliations
  • Johns Hopkins University (US)
  • Harvard University (US)
  • University of California San Diego (US)
  • Bank of America (US)
  • University of Cincinnati (US)
  • Duke University (US)
  • Yale University (US)
  • National Institutes of Health (US)
  • University of North Carolina at Chapel Hill (US)
  • Columbia University (US)
Corresponding author
Daumit, Gail L.
ORCID
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2008-10
Volume
105
Issue
1-3
Pages
175-187
ISSN
0920-9964 (ISSN-L)
DOI
10.1016/j.schres.2008.07.006
PMC
PMC2614656
OpenAlex
W2107325590
Cited by
223
References
44
Citations by year
2026: 2 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 11 · 2018: 11 · 2017: 13 · 2016: 10 · 2015: 20 · 2014: 16 · 2013: 24 · 2012: 20
FWCI
14.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (1MH900001)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
antipsychotic drugs, coronary heart disease risk
MeSH terms
Adult, Coronary Disease, Female, Follow-Up Studies, Humans, Hypertension, Longitudinal Studies, Male, Obesity, Patient Dropouts, Risk Factors, Schizophrenia, Schizophrenic Psychology, Smoking, Antipsychotic Agents, Weight Gain, Comorbidity, Treatment Outcome, Outcome Assessment, Health Care, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review